{"id":"https://openalex.org/W3102590849","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","title":"725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy","display_name":"725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy","publication_year":2020,"publication_date":"2020-11-01","ids":{"openalex":"https://openalex.org/W3102590849","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","mag":"3102590849"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0725","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108728970","display_name":"Linda M\u00e5rtensson","orcid":"https://orcid.org/0009-0002-9518-7359","observed_orcids":["https://orcid.org/0009-0002-9518-7359"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Linda M\u00e5rtensson","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023906837","display_name":"Mathilda Kovacek","orcid":"https://orcid.org/0009-0002-5156-7261","observed_orcids":["https://orcid.org/0009-0002-5156-7261"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Mathilda Kovacek","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042180365","display_name":"Petra Holmkvist","orcid":"https://orcid.org/0000-0002-5324-5170","observed_orcids":["https://orcid.org/0000-0002-5324-5170"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Petra Holmkvist","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013449455","display_name":"Monika Semmrich","orcid":"https://orcid.org/0009-0007-9833-9772","observed_orcids":["https://orcid.org/0009-0007-9833-9772"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Monika Semmrich","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062770901","display_name":"Carolin Svensson","orcid":"https://orcid.org/0009-0000-8434-8503","observed_orcids":["https://orcid.org/0009-0000-8434-8503"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Carolin Svensson","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070337814","display_name":"Therese Blidberg","orcid":"https://orcid.org/0009-0004-1278-0830","observed_orcids":["https://orcid.org/0009-0004-1278-0830"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Therese Blidberg","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066791503","display_name":"Carl Roos","orcid":"https://orcid.org/0000-0002-1525-1430","observed_orcids":["https://orcid.org/0000-0002-1525-1430"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Carl Roos","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000250788","display_name":"Andr\u00e9s McAllister","orcid":"https://orcid.org/0009-0006-5510-444X","observed_orcids":["https://orcid.org/0009-0006-5510-444X"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Andres McAllister","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011445115","display_name":"Mimoza Demiri","orcid":"https://orcid.org/0000-0003-1663-1010","observed_orcids":["https://orcid.org/0000-0003-1663-1010"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Mimoza Demiri","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007108884","display_name":"Marie Borggren","orcid":"https://orcid.org/0009-0001-0346-1676","observed_orcids":["https://orcid.org/0009-0001-0346-1676"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Marie Borggren","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065612884","display_name":"Ingrid Karlsson","orcid":"https://orcid.org/0009-0006-2466-919X","observed_orcids":["https://orcid.org/0009-0006-2466-919X"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Ingrid Karlsson","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013771543","display_name":"Bj\u00f6rn Frend\u00e9us","orcid":"https://orcid.org/0000-0003-3177-8686","observed_orcids":["https://orcid.org/0000-0003-3177-8686"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Bj\u00f6rn Frendeus","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049258782","display_name":"Ingrid Teige","orcid":"https://orcid.org/0009-0007-5996-3396","observed_orcids":["https://orcid.org/0009-0007-5996-3396"]},"institutions":[{"id":"https://openalex.org/I4210141808","display_name":"BioInvent (Sweden)","ror":"https://ror.org/047866h90","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210141808"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Ingrid Teige","raw_affiliation_strings":["BiInvent International, Lund, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BiInvent International, Lund, Sweden","institution_ids":["https://openalex.org/I4210141808"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210141808"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A434.1","last_page":"A434"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9580000042915344,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9580000042915344,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.03220000118017197,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.003599999938160181,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tnfr2","display_name":"TNFR2","score":0.8889999985694885},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.7559999823570251},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.7039999961853027},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.6480000019073486},{"id":"https://openalex.org/keywords/anti-pd-1-combination-therapy","display_name":"anti-PD-1 combination therapy","score":0.609000027179718},{"id":"https://openalex.org/keywords/fc-gamma-receptor","display_name":"Fc gamma receptor","score":0.6240000128746033},{"id":"https://openalex.org/keywords/treg-depletion","display_name":"Treg depletion","score":0.9710000157356262},{"id":"https://openalex.org/keywords/cd8-t-cell-expansion","display_name":"CD8+ T cell proliferation","score":0.9259999990463257},{"id":"https://openalex.org/keywords/tumor-associated-myeloid-cells","display_name":"tumor-associated myeloid cells","score":0.9850000143051147},{"id":"https://openalex.org/keywords/cynomolgus-monkey-toxicity","display_name":"cynomolgus monkey toxicity","score":0.7509999871253967},{"id":"https://openalex.org/keywords/receptor-occupancy","display_name":"receptor occupancy","score":0.6380000114440918},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7059999704360962},{"id":"https://openalex.org/keywords/humanized-mouse-model","display_name":"humanized mice","score":0.7390000224113464},{"id":"https://openalex.org/keywords/no-observed-adverse-effect-level","display_name":"no-observed-adverse-effect level","score":0.5059999823570251}],"concepts":[{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.6115102171897888},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.6111315488815308},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.604517936706543},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.598094642162323},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5711323022842407},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5542136430740356},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.5429056286811829},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4753812849521637},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.45420098304748535},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4340152144432068},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42122071981430054},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3759990930557251},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35631346702575684},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19786763191223145}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2020-sitc2020.0725","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:baba49f749e844cd8cfdc68f13573c43","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/baba49f749e844cd8cfdc68f13573c43","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0725","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0725","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4282943739","https://openalex.org/W4399662578","https://openalex.org/W7222247811","https://openalex.org/W4388047789","https://openalex.org/W4388047848","https://openalex.org/W3083762506","https://openalex.org/W7169614479","https://openalex.org/W7118177497","https://openalex.org/W4282965089","https://openalex.org/W2977721298"],"abstract_inverted_index":{"Background":[0],"The":[1,29,100,157,402],"pleiotropic":[2],"TNF-alpha:TNFR":[3],"axis":[4],"plays":[5],"a":[6,49,96,112,136,161,167,187,207,346,354],"central":[7],"role":[8],"in":[9,82,91,135,154,200,206,229,264,269,315,385,390,396,413,419,448],"the":[10,14,55,145,165,212,220,286,318,340,382,439,453],"immune":[11,27,230],"system.":[12],"While":[13],"cellular":[15],"expression":[16,22],"of":[17,32,114,125,144,190,240,302,312,317,425,434,441],"TNFR1":[18],"is":[19,23,353,364],"broad,":[20],"TNFR2":[21,34,69],"mainly":[24],"restricted":[25],"to":[26,43,104,218,242,292,326,344,380],"cells.":[28,128],"therapeutic":[30,329,360],"potential":[31],"targeting":[33],"for":[35,181,288,335,394,444],"cancer":[36,233,392],"treatment":[37],"has":[38],"been":[39],"previously":[40],"indicated":[41],"and":[42,59,67,76,90,108,123,164,175,205,227,256,261,267,284,359,362,372,429,464],"gain":[44],"further":[45,198],"insight,":[46],"we":[47,322],"characterized":[48],"wide":[50],"panel":[51],"antibodies,":[52],"generated":[53],"from":[54],"n-CoDeR":[56],"F.I.R.S.T\u2122":[57],"target":[58],"antibody":[60],"discovery":[61],"platform.":[62],"We":[63],"identified":[64],"parallel":[65],"human":[66,146],"mouse":[68,138,209,232],"specific,":[70],"complete":[71],"ligand":[72],"(TNF-alpha)":[73],"blocking":[74],"antibodies":[75],"could":[77,323],"show":[78,324],"potent":[79],"anti-tumor":[80],"activity":[81],"several":[83],"immune-competent":[84],"models,":[85],"both":[86],"as":[87],"single":[88],"agent":[89],"combination":[92,113],"with":[93,251,370,415],"anti-PD1":[94],"using":[95,133],"BI-1808":[97,134,148,213,241,289,363],"murine":[98,214],"surrogate.":[99],"mechanism-of-action":[101],"was":[102,160,197,216,290,333,407],"shown":[103],"be":[105,293],"FcgR":[106],"dependent":[107],"likely":[109],"mediated":[110],"through":[111],"intra-tumor":[115],"T":[116,120,201,270],"reg":[117],"depletion,":[118],"CD8+":[119],"cell":[121,202],"expansion":[122],"modulation":[124],"tumor-associated":[126],"myeloid":[127],"These":[129],"findings":[130],"were":[131,152,178,245,272,282,309,378,450],"confirmed":[132],"humanized":[137,208],"model.":[139,210],"Methods":[140],"To":[141],"address":[142],"safety":[143],"lead-candidate":[147],"two":[149,303,337],"toxicological":[150],"studies":[151,297,377],"performed":[153],"cynomolgus":[155,243],"monkeys.":[156],"first":[158],"study":[159,163,169,219,389,403],"dose-range-finding":[162],"second":[166],"GLP":[168],"where":[170],"three":[171],"doses":[172,368],"(2,":[173],"20":[174],"200":[176,294],"mg/kg)":[177],"given":[179],"weekly":[180,238],"four":[182],"consecutive":[183],"weeks":[184,304],"followed":[185],"by":[186,409,452],"recovery":[188],"period":[189],"eight":[191],"weeks.":[192],"In":[193],"addition,":[194],"cytokine":[195,313],"release":[196,314],"studied":[199],"stimulation":[203],"assays":[204],"Moreover,":[211],"surrogate":[215],"used":[217,379,443],"relationship":[221],"between":[222,357],"dose,":[223],"receptor":[224,306],"occupancy":[225],"(RO)":[226],"efficacy":[228],"competent":[231],"experimental":[234],"models.":[235],"Results":[236],"Four":[237],"administrations":[239],"monkeys":[244,406],"well":[246,365],"tolerated":[247,366],"at":[248,274,305,367],"all":[249,275],"doses,":[250],"no":[252,257,310],"associated":[253,369],"clinical":[254],"signs,":[255],"histopathological":[258],"changes.":[259],"Non-adverse":[260],"reversible":[262],"increases":[263],"neutrophil":[265],"counts":[266],"decreases":[268],"cells":[271],"observed":[273,283],"dose":[276,384],"levels.":[277],"No":[278],"drug-related":[279],"adverse":[280],"events":[281],"consequently":[285],"NOAEL":[287],"determined":[291],"mg/kg.":[295],"Pharmacokinetic":[296],"demonstrated":[298],"an":[299],"expected":[300],"half-life":[301],"saturation.":[307],"There":[308,352],"indications":[311],"any":[316],"systems":[319],"tested.":[320],"Finally,":[321],"that":[325],"achieve":[327],"max":[328],"effect,":[330],"sustained":[331,373],"RO":[332,358],"needed":[334],"approximately":[336],"weeks,":[338],"covering":[339],"time":[341],"it":[342],"takes":[343],"generate":[345],"full":[347],"adaptive":[348],"Immune":[349],"response.":[350],"Conclusions":[351],"clear":[355],"association":[356],"effect":[361],"high":[371],"RO.":[374],"Collectively,":[375],"these":[376],"determine":[381],"starting":[383],"upcoming":[386],"phase":[387],"I/II":[388],"solid":[391],"aiming":[393],"first-patient":[395],"during":[397],"December":[398],"2020.":[399],"Ethics":[400,457],"Approval":[401],"on":[404,438],"cynomolgous":[405],"conducted":[408],"Citox/Charles":[410],"River":[411],"Laboratories":[412],"compliance":[414],"animal":[416],"health":[417],"regulations,":[418],"particular:":[420],"Council":[421],"Directive":[422],"No.":[423,432],"2010/63/EU":[424],"22":[426],"September":[427],"2010":[428],"French":[430],"decree":[431],"2013-118":[433],"01":[435],"February":[436],"2013":[437],"protection":[440],"animals":[442],"scientific":[445],"purposes.":[446],"Studies":[447],"mice":[449],"approved":[451],"Swedish":[454],"Animal":[455],"Experiment":[456],"Board,":[458],"ethical":[459],"permit/ethical":[460],"license":[461],"numbers":[462],"5.2.18-17196/2018":[463],"5.8.18-03333/2020":[465]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2020-11-23T00:00:00"}